SynthesisDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
The effects of resveratrol on glycemic indices and lipid profile in patients with type 2 diabetes: an umbrella review and meta-analysis.
Synthesis in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowing evidence supports the therapeutic role of nutraceuticals as complementary and alternative therapies in patients with type 2 diabetes mellitus (T2DM). Resveratrol, a natural polyphenol compound has been shown to modulate metabolically disturbances include insulin resistance and lipid profile disturbances.
objectivesThis umbrella review and meta-analysis study conducted to assess the effect of resveratrol on glycemic indices and lipid profile in T2DM.
methodsThe study was performed by using the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines (PRISMA) checklist. The PubMed, Web of Sciences, and Google Scholar databases were used to search the published papers up to 2025. The AMSTAR questionnaire was used for assessing the quality of eligible studies. Additionally, The Cochran Q test and I
resultsOf 10 meta-analyses evaluating the resveratrol effects on glycemic indices and lipid profile showed no significant effects on fasting blood sugar, glycosylated hemoglobin A1c (HbA1c), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglyceride (TG), total cholesterol (TC), despite significant heterogeneity. Nevertheless, based on SMD analyses, resveratrol supplementation showed only significant effects on LDL-C reduction. Also, significant decline in serum insulin level was observed for sample size ≥ 500 and study number ≥ 10.
conclusionGiven the high heterogeneity and limitations attributed to the study, resveratrol supplementation was not considered as a beneficial agent in declining glycemic indices and lipid profile in patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.